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Objectives Aggressive cancer therapy places patients at a greater risk for oral complications. Cancer patients suffer from 
oral toxic effects secondary to antineoplastic therapy (radiotherapy and chemotherapy). The aim of this review is 
management of the head and neck   cancer patients that specifically emphasizes the prevention and treatment of oral 
and   dental complications associated with cancer therapy. 
Methods In this narrative review article, the specialized databases such as PubMed, PubMed Central, MEDLINE, EBSCO, 
Science Direct, Scopus from 2008 to 2018 were used to find relevant documents by using Mesh terms: Chemotherapy, 
Radiotherapy, oral consideration, head and neck. 
Results The data were categorized in: Complications of head and neck radiotherapy and its management (Xerostomia,  
Oral Infection, Oral Mucositis, Osteoradionecrosis), Complications of head and neck chemotherapy and its 
management (Mucosal toxicity, Dental alterations, Neurological disorders, Salivary alterations, Dysgeusia, Infections, 
Bleeding tendency, Osteonecrosis of the jaws due to bisphosphonates).  
Conclusion In order to minimize   morbidity in the head and neck cancer patients, it is recommended for consulting to   
dental health care providers   before, during and after cancer therapy.  




Acute and chronic reactions occur during the course of 
radiotherapy and chemotherapy. Pretreatment diagnosis and 
treatment is critical in preventing the serious squeal of 
cancer therapy and improving the patient’s quality of life
1
. 
A thorough oral examination is recommended, comprising 
an evaluation of the dentition and surrounding supportive 
periodontium, and a complete radiographic survey 
conducted as early in the course of treatment as possible. 
During this examination, hopeless and non-restorable teeth 
must be removed before treatment to minimize the risk for 
the development of complications, such as odontogenic 
facial abscesses and osteoradionecrosis
2, 3
. The early 
recognition of opportunistic infections, such as candidiasis 
or herpetic infections and their management also will 
improve the patient’s overall health
4
. Communication 
between the physician and dentist must be established and 
continued throughout the patient’s course of treatment. The 
dentist must have an understanding of the patient’s medical 
history, diagnosis, staging, and planned therapy to develop 
an appropriate treatment plan
5
. Additionally, performing 
oral surgery on an immunosuppressed patient who has 
thrombocytopenia and neutropenia may result in serious 
complications not foreseen by the treating dentist 
2, 5
. Dental 
decay may progress to the vital pulpal tissues of the tooth, 
leading to an increase in pain and sensitivity and often 
causing necrosis of the vital pulp and the formation of an 
abscess
6
. The abscessed pulpal tissues may not present with 
symptoms and may spread rapidly to involve the fascial 
planes of the head and neck region, resulting in space 
infections or extensions beyond the head and neck region
6, 7
. 
These infections may prove life-threatening and difficult to 
manage in the immunocompromised patient
6
. The dentist 
plays a critical role in the multidisciplinary approach to 
treating the head and neck cancer patients
8, 9
. The dental 
examination should include a detailed clinical examination 
with a full-mouth radiographic survey to ensure that all 
dental disease is revealed
9
.  
Complications of head and neck radiotherapy and its 
management 
The oral tissues directly affected by head and neck radiation 
therapy include the mucosal membranes, the salivary 
glands, the jaw muscles and bone
10-13
. Dry mouth 
(xerostomia) is a common and significant consequence of 
head and neck radiotherapy. patients with xerostomia are 
more susceptible to rampant caries, periodontal disease and 
oral fungal and bacterial infections
14
. Mucositis, 
characterized by inflammation and ulceration of the oral 
mucosa, is the most significant acute side effect reported by 
patients and is a potential source of life-threatening 
infection
14
. Almost all patients undergoing head and neck 
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radiation therapy experience mucositis approximately the 
third week of treatment
14, 15
. Also radiotherapy can induce 
fibrosis around the muscles of mastication, leading to 
trismus. It is believed that jaw exercises may limit the 
severity of trismus, but they will not mobilize fibrosis once 
it has occurred
16
.  Bone exposed to high levels of radiation 
undergoes irreversible physiologic changes including 
narrowing of the vascular channels (endarteritis), which 
diminishes blood flow to the area, and loss of osteocytes. 
The bone essentially becomes nonvital, which leads to 




1.1.  Xerostomia 
Xerostomia is a common and significant 
consequence of head and neck radiotherapy. 
Systemic sialagogues increase the production of 
saliva from functional glands. There is no optimal 
substitute for saliva. Pilocarpine (Salagen) and 
Cevimeline (Evoxac) have shown promising effects 
in increasing saliva but is only effective for salivary 
glands with residual function
18 , 19. 
 Two alternative 
medications that may be beneficial in stimulating 
salivary glands include anethole trithione (Sialor) 
and bethanechol (Urecholine)
20
. Although saliva 
replacements such as UniMist (Westons Health), 
Mouth Kote (Parnell Pharmaceuticals) and Oral 
Balance Gel (Laclede Pharmaceuticals) are poor 
salivary substitutes, as they primarily attempt to 
mimic the texture of saliva but do not simulate the 
rheologic properties.  Oral Balance Gel may be the 
best accepted by patients because of its extended 
duration of effect. Sugarless gum or lozenges may 
stimulate salivary secretion in patients with residual 
salivary gland function
18
. Sugar-free popsicles, plain 
ice cubes or ice water may be used to keep the 
mouth cool and moist. Eating foods high in ascorbic 
acid, malic acid or citric acid will stimulate the 
glands to increase salivary flow, but this measure is 
not recommended in dentate patients because the 
acidity can further irritate oral tissues and contribute 
to the demineralization of teeth
18
. For the prevention 
of rampant dental demineralization and caries, 
patients should apply a 1.1% neutral sodium fluoride 
gel daily (for at least 5 minutes), using a custom 
fitted vinyl tray if possible
9
. This protocol may be 
started on the first day of radiation therapy and 
continued daily as long as salivary flow rates are 
low. High-potency fluoride brush-on gels and 
dentifrices may be considered in those who are 
unable or unwilling to comply with the use of 
fluoride trays
8
.   
1.2. Oral Infection 
Health care providers should be concerned about 
infections in cancer patients. A fungal, bacterial or 
viral culture is recommended if infection is 
suspected
4, 21
. In patients undergoing head and neck 
radiotherapy, Candida colonization tends to increase 
throughout the course of treatment and remains 
increased if xerostomia occurs
4
. Nystatin rinses are 
the most widely prescribed treatment for oral fungal 
infections, despite a lack of proven efficacy. 
Nystatin has an unpleasant flavor and may cause 
nausea and vomiting
4
, and its high sucrose content is 
a major concern in dentate patients. For more severe 
infections, the use of a systemic antifungal 
medication such as fluconazole (Diflucan) or 
amphotericin B is recommended. Systemic 
amphotericin B must be used with caution because 
of its potential to cause liver toxicity
22
. Topical 
antifungals to consider include clotrimazole, 
ketoconazole and chlorhexidine. Chlorhexidine 
gluconate 0.12%; (Peridex), an antimicrobial rinse, 
has both antifungal and antibacterial properties in 
addition to antiplaque effects; however, its value is 
still unconfirmed. Its tendency to stain teeth and its 
alcohol content, which can irritate inflamed tissues, 
are drawbacks
22
. If chlorhexidine is used, it is 
important to note that nystatin and chlorhexidine 
should not be used concurrently, because 
chlorhexidine binds to nystatin, rendering both 
ineffective 
22
, furthermore, chlorhexidine should be 
used at least 30 minutes before or after the use of 
any other topical agents with which it may bind. 
For cancer patients with viral infections, such as 
Herpes simplex 1, acyclovir (Zovirax, 
GlaxoSmithKline) or derivatives are recommended 
for both prophylaxis and treatment
21, 23
. Pencyclovir 
(Denavir, GlaxoSmithKline), a newer topical 




1.3. Oral Mucositis 
Mucositis, characterized by inflammation and 
ulceration of the oral mucosa, and is the most 
significant acute side effect of radiotherapy. The use 
of a common oral rinse
24
, is often suggested, but no 
studies have confirmed any beneficial effect upon 
mucositis. It has been suggested that patients begin 
prophylactic rinses with chlorhexidine to prevent the 
onset of microbial infection, gum inflammation and 
bleeding, and to reduce the risk of caries. While 
some authors report that a chlorhexidine oral rinse 
has potential effects on mucositis, others report no 
effects have been reported for radiation induced 
mucositis to date
25
. Use of other oral rinses, 
including commercial alcohol-based mouthwashes 
and hydrogen peroxide rinses, should be 
discontinued because of their drying and irritating 
effects on the oral mucosa
25
. The discomfort of 
mucositis can be reduced with coating agents, 
topical anesthetics and analgesics, although systemic 
analgesics are frequently needed
14
. Aluminum 
hydroxide/magnesium hydroxide (milk of magnesia- 
Maalox) and sucralfate have been suggested as 
coating agents for the oral mucosa. Sucralfate 
             Review Article 
Mahin Bakhshi, et al.     Dental management in head and neck cancer                                                                                                           
  
 
Journal Dental School; Vol 36, No.3, Summer 2018; 108-114  110  
suspension may also be helpful in the treatment of 
oral pain, although the effect on mucositis has not 
been clearly documented
26
.  Topical anesthetics used 
in rinse form may result in intense but short-term 
anesthesia. However, the localized anesthesia can 
increase the risk of aspiration, and their systemic 
absorption can cause cardiac effects
27
. When oral 
mucosal pain is present, benzydamine hydrochloride 
(Tantum), doxepin suspension 0.5% or an 
antihistamine such as diphenhydramine can be 
prescribed
27
. Benzydamine is the only medication 
available that has been shown in multicentre, 
double-blind controlled studies to reduce mucositis 
and pain in patients with head and neck cancer
28
.  
Topical anesthetics, such as benzocaine, viscous 
lidocaine and topical benzocaine can be applied 
locally to sites of pain with a swab or a soft vinyl 
mouth guard
29
. Of all available mouth rinses that can 
be used as treatments for mucositis, the least costly 
and easiest for patients to prepare is a simple 
mouthwash comprising a teaspoon (10 mL) of salt 
and a teaspoon (10 mL) of baking soda (sodium 
bicarbonate) in 8 ounces (250 mL) of water. A 
comparison among salt and soda mouthwashes, 
mouthwashes prepared from lidocaine and 
diphenhydramine with Maalox, and mouthwashes of 
0.12% chlorhexidine gluconate found that the 3 
options were equally effective in the treatment of 
chemotherapy-induced mucositis
29
.   
 
1.4.  Osteoradionecrosis 
Osteoradionecrosis (ORN) is irreversible, 
progressive devitalization of irradiated bone. The 
condition is characterized by necrotic tissue and 
bone that fails to heal spontaneously. Most cases of 
ORN occur in the mandible, where vascularization is 
poor and bone density is high
30
. Clinical 
manifestations of ORN may include pain, exposed 
necrotic bone, orofacial fistulas, pathologic fracture 
and suppuration
30
. One-third of ORN cases occur 
spontaneously. Many cases with ORN have been 
initiated by trauma from extraction of teeth. The 
incidence of ORN is twice as high in dentate patients 
as it is among edentulous patients. Poor oral hygiene 
and use of tobacco and alcohol may also lead to 
rapid onset of ORN. It is optimal to allow 14 to 21 
days for healing of the alveolar bone before 
beginning radiation therapy .10 Over the years, ORN 
has been treated by numerous methods with variable 
success
31
. Hyperbaric oxygen therapy is an 
adjunctive treatment for ORN, often used in 
conjunction with surgery, and has been associated 




2. Complications of head and neck chemotherapy and its 
management  
The oral complications of chemotherapy are either a 
result of direct action of the drug upon the oral 
mucosa, or an indirect consequence of 
chemotherapeutic drug-induced bone marrow 
suppression or myelo suppression
33
.  
2.1.  Mucosal toxicity  
The cells of the oral cavity have a fast turnover rate, 
with a cycle of 7-14 days. This explains the special 
susceptibility of the oral mucosa to the toxic effects 
of cytotoxic drugs
34, 35
. Mucositis manifests as 
reddening (erythema), edema or ulceration that can 
be accompanied by a mild burning sensation. 
Extreme presentations in turn are characterized by 
large and painful ulcers that have a strong impact 
upon patient quality of life – limiting basic functions 
such as speech, eating or the swallowing saliva. 
Mucositis can often become over-infected, mainly 
with herpes simplex virus or Candida albicans, 
particularly in patients with prolonged neutropenia. 
Correct oral hygiene and a good gingival condition 
during chemotherapy are associated to a lesser 
incidence and severity of mucositis
35
. About using of 
drugs or substances for the prevention and treatment 
of mucositis, the literature offers contradictory 
information
35
. Good results have been reported with 
the application of ice before and during 
chemotherapy
36
, and also with the use of ise-ganan 
HCl
37
.  Other treatment such as palifermin
38
, 
granulocyte colony stimulating factor (G-CSF),  oral 
glutamine, and macrophages in rinses, the topical 
application of polyvinylpyrrolidone (PVP) and 
hyaluronic acid
39
, and low-intensity laser 
phototherapy, have been related to a decrease in the 
appearance and severity of mucositis
40
. 
2.2.  Dental alterations 
Chemotherapy can cause a range of aesthetic and 
functional dental problems, mostly in children 
treated before 5 years of age. However, prepubertal 
children are also at risk of suffering such late effects 
in contrast to radiotherapy, which only affects the 
cells of the irradiated zone, chemotherapy exerts a 
systemic effect. Due to the short half-life of 
cytostatic drugs, the dental defects are generally 
localized, and are secondary to transient changes in 
odontoblast function, rather than apoptosis. 
The shape and size of the crown in the temporal 
dentition are not affected, since crown morphology 
is determined before birth. However, in the case of 
the permanent dentition, we can observe 
macrodontia with a prevalence of 2.2-5.2%, due to 
the action of certain chemotherapeutic drugs such as 
vinblastine and vincristine upon the mature 
odontoblasts and ameloblasts
41
.  Chemotherapy also 
causes morphological anomalies of the dental roots. 
In this context, in children under 5 years of age we 
can observe alterations of the roots of the upper and 
lower premolars, while older children show 
alterations of the roots of the upper and lower 
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molars, premolars and canines
42, 43
. The action of 
cytostatic drugs upon the microtubules of the 
odontoblasts interrupts the formation of collagen 
fibrils and dentinal matrix secretion, giving rise to 
thin and sharp-pointed roots. Also chemotherapy 
causes agenesis hypodontia and hypoplasia
43
. 
Some authors have described an increased incidence 
of caries in children subjected to chemotherapy, 
though the data are controversial, since caries may 
result from an increased use of rinses, often with a 
high sugar content, to treat hypo salivation
44
. In 
adults, a number of studies have reported an increase 
in caries in patients subjected to chemotherapy. 
Children scheduled for chemotherapy should 
undergo a thorough clinical and radiological 
evaluation by the dentist
44
. Periodic follow up should 
be made, every 6 months. The recommended tooth 
brushing frequency varies, though at least two daily 
brushings are advised, using fluorated toothpaste. 
Chlorhexidine varnish also can be applied twice a 
day as a preventive measure against caries
44
. 
2.3.  Neurological Pain 
Neurotoxicity accounts for 6% of all oral 
complications, causing pain similar to pulpitis and 
discomfort. The pain sensation is constant and of 
sudden onset, affecting the region of the lower 
molars in the absence of dental disease. An oral and 
radiological exploration should be made to 
distinguish the pain from that of pulp origin. The 
symptoms usually disappear one week after 
chemotherapy. In some cases dental hypersensitivity 
can manifest weeks or months later. In these cases 
topical fluoride or the use of a desensitizing 
toothpaste may lessen the symptoms
45
. 
2.4.  Salivary alterations 
 Salivary immunoglobulin and PH 
Chemotherapy decreases the salivary production of 
immunoglobulins also  affects a series of salivary 
components, such as immunoglobulins, amylases, 
peroxidases and other proteins
46
. Decreasing in IgG 
and IgA could explain some of the oral 
complications of chemotherapy. Decrease in IgA 
has been associated to the appearance of mucositis 
in patients receiving chemotherapy. 
Some authors have reported a modification in 
salivary buffer capacity after the administration of 
chemotherapy
46
. However, other investigators have 
observed no significant variations following the 
administration of cytostatic agents. 
 Xerostomia 
Chemotherapy can give rise to a temporary but 
clinically significant decrease in salivary flow that 
improves as the bone marrow recovers
20
.  Such a 
decrease in salivary flow in turn favors the 
appearance of mucositis
19
. The symptoms of 
xerostomia or dry mouth include dryness, burning 
sensation or discomfort (particularly of the tongue), 
cracked lips, changes in the tongue surface, and 
problems in wearing removable dentures or 
drinking liquids
18
. The condition tends to be 
preceded by a metallic taste sensation that 
subsequently can lead to dysgeusia and glossodynia 
secondary to the effects of chemotherapy upon the 




In treating xerostomia it is advisable to maintain 
adequate oral hydration by means of the regular 
intake of water, the use of saliva substitutes or 
cholinergic agonists such as pilocarpine, cevimeline 
or bethanechol (when pilocarpine proves 
ineffective); these measures moreover favor 
integrity of the oral mucosa
18
. 
2.5.  Dysgeusia 
The main cause of dysgeusia in cancer patients is the 
action of radiotherapy and chemotherapy upon oral 
epithelial cell turnover, and the effects of such 
treatments upon nerves, taste buds and olfactory 
receptors
47
. The patients present distorted taste 
sensation, describing a metallic or very salty taste of 
food. These situations can adversely affect patient 
food intake and nutritional condition. Although 
dysgeusia has multiple origins, there are simple 
forms of treatment, such as a reduction of the dose of 
certain chemotherapeutic drugs (e.g., histone 
deacetylase inhibitors), the treatment of oral 
infections, and dietetic counseling
48
.  In relation to 
this latter aspect, it is advisable to increase liquid 
intake with meals, and chew food slowly - thereby 
freeing more flavors and especially increasing saliva 
production. In addition, diversity during meals is 
advisable, in order to prevent taste bud adaptation to 
flavors. Other pharmacological strategies include 
zinc supplements and amifostine .However, the 
results obtained in different clinical trials have not 
been entirely satisfactory, and other treatment 




2.6.  Infections 
Cytostatic agents can affect the bone marrow, 
producing anemia, leukopenia and thrombopenia. As 
a result of their indirect toxicity mechanism, the oral 
cavity becomes more vulnerable to infections 
approximately one week following the 
administration of these drugs. Bone marrow function 
must be evaluated, since the reduction or absence of 
inflammatory phenomena causes the oral tissues to 
appear normal; infections therefore go unnoticed, 
and septicemia may result. It should be noted that 
apart from causing frequent infections, 
agranulocytosis also produces neutropenic ulcers, 
which are characterized by a central necrotic area, no 
perilesional erythematous halo, and irregular 
margins
49
.  These ulcerations are generally large and 
painful and may be covered by a fibrin membrane. 
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They appear in both keratinized and non-keratinized 
tissues and are associated with granulocyte counts of 
under 800 cells/μl
49
.   
2.7.  Bleeding Tendency 
Bleeding tendency in the oral cavity usually appears 
after trauma during chewing in patients with pre-
existing periodontal disease- especially patients with 
prior gingivitis and a platelet count of less than 
20,000 platelets/mm
3
. Clinically, we can observe 
petechiae, ecchymosis, and hematomas or diffuse 
bleeding in any location of the oral cavity. Oral 
rinses with 0.12% chlorhexidine avoid over infection 
and can help eliminate remaining blood, though 
caution is required not to disturb the blood clots, 
since this may lead to further bleeding
50
. The 
treatment of choice in cases of bleeding consists of 
vasoconstrictors such as topical norepinephrine, 
mucoadherent tissue protectors such as 
cyanoacrylate, and coagulation-favoring drugs such 
as topical thrombin or hemostatic collagen, which 
organize and stabilize the blood clots
50
. In 
individuals subjected to chemotherapy who require 
invasive dental treatment, the hematological 
condition of the patient must be taken into account, 
with consultation of the supervising oncologist. In 
the presence of a platelet count of under 50,000 
platelets/mm3, it is advisable to provide invasive 
dental treatment in the hospital setting, following 
transfusion assessment. 
2.8.  Osteonecrosis of the jaws  
Bisphosphonates (BPs) are potent inhibitors of 
osteoclastic bone reabsorption and have been used 
for decades for the treatment of osteoporosis, 
malignant hypercalcemia, bone metastases and 
myeloma. The development of osteonecrosis of the 
jaws (ONJ) has been associated to a number of 
general risk factors, such as the type of BP 
administered, the duration of treatment, the type of 
neoplasm, the existence of concomitant treatments 
(chemotherapy, head and neck radiotherapy, 
corticosteroids, thalidomide or bortezomib), and the 
presence of other disease conditions (anemia, 
diabetes, obesity, hypercalcemia and coagulation 
disorders)
51
. Local risk factors in turn include 
dentoalveolar surgery, the mandibular location, bone 
protuberances (torus, mylohyoid crest) and 
concomitant oral disease (periodontal or dental 
infections)
51
. Other contributing cofactors are 
alcohol, smoking, deficient oral hygiene, obesity and 
old age. Clinically, the onset of ONJ can be 
nonspecific. The patient may describe discomfort 
around a tooth, a lack of healing after tooth 
extraction, or ulceration of the oral mucosa
52, 53
. As 
the lesions advance, the patient may develop pain, 
exposure of necrotic bone, fistulization, purulent 
secretion, alveolar nerve paresthesia, dental 
mobility, involvement of the maxillary sinus, and 
mandibular fracture
54
. If the patient is receiving 
treatment with BPs, it is advisable to evaluate the 
oral cavity every 6-12 months. The treatment of ONJ 
is controversial, and no effective or fully consensus-
based guidelines have been established, though a 
number of management strategies have been used, 
such as the interruption of BPs, surgical treatment, 
the use of hyperbaric oxygen, and the application of 
ozone, laser surgery, or low-intensity laser therapy 
.Research is still being conducted on the efficacy of 
the treatment of ONJ with pentoxyphylline, α-
tocopherol or teriparatide. Most authors agree that 
conservative management of ONJ is the best 
approach
55
, since mucosal healing can be achieved in 
at least 23-53% of all patients by adopting less 





Radiotherapy and chemotherapy have been used in the head 
and neck cancer treatment. However, these therapies can 
cause several adverse reactions that affect quality of life in 
the patients, it is very important that health care providers 
are familiarized with these complications that may result 
from anti-neoplastic therapies. Multidisciplinary treatment, 
including medical team, oral care providers, nutritionists 
and psychologists, is the best option in order to minimize or 
even prevent such complications.  
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